Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05012644 · ClinicalTrials.gov registry record
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 197
- Enrollment target
NCT05012644 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 197 participants.
The verdict
NCT05012644 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 197 participants
- Enrollment target
Study Summary
This study aims to assess real-world tumor response in pre/perimenopausal HR+/HER2- metastatic breast cancer (MBC) patients initiating palbociclib + aromatase inhibitor (AI) or AI alone as first-line therapy during the period on or after 01 January 2010 to on or before 30 June 2020. Data will be obtained from structured data fields within an electronic health record (EHR) database and will be supplemented by additional unstructured data collected through a targeted chart review.
Interventions
- DRUG Aromatase inhibitor
- DRUG Palbociclib + aromatase inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2021-12-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05012644
The ClinicalTrials.gov registry entry for NCT05012644 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aromatase inhibitor is the first listed.
NCT05012644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05012644 about?
NCT05012644 is a clinical study titled "Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone". This study aims to assess real-world tumor response in pre/perimenopausal HR+/HER2- metastatic breast cancer (MBC) patients initiating palbociclib + aromatase inhibitor (AI) or AI alone as first-line therapy during the period on or after 01 January 2010 to on or before 30 June 2020. Data will be obt...
What is the current status of trial NCT05012644?
This trial is currently completed. The enrollment target is 197 participants. The study started on 2021-07-16. Estimated completion is 2021-12-09.
What interventions are being tested in trial NCT05012644?
The interventions under investigation include: Aromatase inhibitor (DRUG), Palbociclib + aromatase inhibitor (DRUG).
Who is sponsoring clinical trial NCT05012644?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.